BTIG analyst Ryan Zimmerman initiated Stryker with a Buy rating and a price target of $187 as part of his broader research note titled "Riding the Robotic Wave in Orthopedics". The analyst cites the company's ability to generate consistent organic revenue growth across all its divisions at "multiples" of the broader medical technology market while also pointing to its "diversified revenue composition and consistency of execution". Despite the premium valuation, Zimmerman notes that Stryker is the stock to own over the long-term, adding that the company is also continually updating its product mix with strategic tuck-in acquisitions that leverage its sales channels.